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AD patients were not on anti-alzheimer’s medication both in
2005 and 2006. Closer scrutiny on these trends is required to
alleviate AD disease burden.
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TREATMENT PATTERNS AND PATIENT CHARACTERISTICS IN
PARKINSON’S DISEASE (PD): RESULTS FROM A LARGE
MULTI-CENTER NEUROMONITOR INITIATIVE IN SPAIN
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OBJECTIVES: To assess treatment patterns and associated
patient characteristics among PD patients in a multi-center setting
in Spain, and generate estimates at country-level. METHODS:
NeuroMonitor is an annual study conducted among neurologists
in hospitals and private practices to collect chart data (disease/
patient characteristics & treatment patterns) on patients receiving
medications to treat neurologic conditions during the study
window/encounter. Current analysis of PD patients in Spain uti-
lized 2006 data from 102 neurologists & 1030 patient charts. A
multi-stage weighting method at physician/patient level was
employed to extrapolate data to Spain population. RESULTS:
Among patients receiving neurologic agents in 2006, over 85,000
patients were estimated to have PD (average age: 71 yrs; female:
40%; disease stages per H&Y scale, I: 13%, II: 37%, III: 34%, IV:
12%, V: 1%). Majority (87%) of PD-patients were diagnosed by
neurologists, and 42%, 21% & 37% of patients were diagnosed
within 1-yr, 1–2 yrs & >2-yrs respectively. Key comorbidities
included: Hypertension (53%), dyslipidemia (29%), diabetes
(26%), osteoarthritis (24%), depression (26%) & anxiety/
dementia (12% each). Majority (98%) of PD-patients rec-
eived anti-parkinson’s medications, with sparse use of antidepres-
sants (2%) and anticholinergics/antipsychotics/anti-alzheimers/
hypnotics-sedatives (1% each). Among those using anti-
parkinson’s medication, utilization patterns varied by disease
severity—levadopa-based: total-77%, mild-62%, moderate-
91%, severe-96%, cabergoline: total-15%, mild-12%, moderate-
16%, severe-20%, pramipexole: total-14%, mild-16%,
moderate-11%, severe-12%, ropinirol: total-11%, mild-
10%,moderate-11%, severe-18%, selegiline: total-9%,mild-9%,
moderate-8%, severe-9%, entacapone: total-7%, mild-3%,
moderate-8%, severe-22%, rasagiline: total-5%, mild-
6%, moderate-4%, severe-5%. CONCLUSION: Almost half of
PD patients were diagnosed within last 1-yr and majority had
moderate disability. In spite of prevalence of psychiatric comor-
bidities, only few patients were on appropriate concomitant medi-
cations. Levodopa-based PD regimen use was widely prevalent,
followed by dopamine-agonists; extent of use differed by disease
severity. Further research iswarranted to assess the impact of these
patterns on long-term outcomes.
PND26
USE OF A COUNSELLING GUIDELINE FORTHE DETECTION
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OBJECTIVES: Drug-related problems (DRPs) are very likely to
occur among patients with Parkinson’s disease (PD). With regard
to the complexity of PD’s long-term treatment regimen, there is
an increasing need for the systematic monitoring of drug thera-
pies in outpatient settings. The aim of this study was to evaluate
the advantages of a counselling guideline for the detection of
DRPs in Parkinson patients used in community pharmacies.
METHODS: The counselling guideline included standardised
questionnaires on the drug treatment and a checklist of common
DRPs induced by antiparkinsonian agents, part of which were
reported by patients in supervised internet forums. Thirty-two
pharmacies in Germany were recruited for the study. In accor-
dance with the guideline each pharmacy monitored PD patients
for eight months. A total of 112 patients were included to the
study and checked for potential or actual occurrences of DRPs.
The DRPs were then categorised using the Problem Intervention
Documentation (PI-Doc). Medication proﬁles and dose regimens
were adjusted in cooperation with the treating physician where
appropriate. RESULTS: In total, 331 DRPs were identiﬁed. Lack
of medication despite indication, especially for non-motor symp-
toms (26.6%), adverse drug reactions (12.4%), inappropriate
time of administration (10.0%), under-dosage (9.7%) and drug
interactions (9.4%) accounted for the highest percentage of
DRPs. Pharmacists’ use of the counselling guideline led to an
improvement of the drug regimen in more than half of the cases
(52.6%). In addition, four patients were identiﬁed who were
misdiagnosed with PD. CONCLUSION: The disease speciﬁc
counselling guideline supports the detection of DRPs and should
be part of routine assessment of patients with PD.
NEUROLOGICAL DISORDERS—Methods and Concepts
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OBJECTIVES: To demonstrate the feasibility of a person-
level net beneﬁts (NB) approach to estimating marginal cost-
effectiveness, with an application to disease-modifying drugs
(DMDs) in multiple sclerosis (MS). The NB approach to estimat-
ing cost-effectiveness has been shown to overcome statistical
issues associated with the conventional incremental cost-
effectiveness ratio. A person-level NB approach can be used to
estimate marginal cost-effectiveness and conﬁdence intervals.
METHODS: The NB variable value for each data point was
calculated as MS-speciﬁc or generic health status (HS), weighted
by a threshold willingness-to-pay per QALY gain (l), less direct
costs (NB = HS.l - (cDMD + cHC)). A ﬁxed effects model
regressed NB against explanatory variables, including years since
MS onset and DMD treatment years. b-coefﬁcients for explana-
tory variables represent their marginal contributions to overall
NB. For DMD treatment years, the l at which b = 0 represents
the threshold willingness-to-pay per QALY, where marginal mon-
etized health outcomes equal marginal (net) costs. The study
population includes all 1995–2004 residents of Nova Scotia,
Canada, with relapsing-onset deﬁnite MS treated with DMDs
under a universal insurance program begun in 1998 and deliv-
ered by the Dalhousie MS Research Unit clinic. Data included
repeat-visit measures of MS-speciﬁc disability (Expanded Dis-
ability Status Scale), generic health-related-quality-of-life (Health
Utilities Index Mark III), DMD costs (cDMD) and annual direct
health care costs (cHC) for physician, hospital and pharmacare
utilization. RESULTS: b-coefﬁcients estimated with the NB
model moved in the expected direction as l was varied. The
b-coefﬁcient on DMD treatment years was strongly negative at
relatively low willingness-to-pay thresholds and increased with l.
CONCLUSION: The person-level NB approach is feasible. It
generates marginal cost-effectiveness estimates that have statisti-
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cal properties superior to conventional estimates of incremental
cost-effectiveness and that do not depend upon an arbitrary
analysis horizon. From an economic perspective, marginal esti-
mates are preferred to incremental, or average, estimates.
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OBJECTIVES: To compare incremental cost effectiveness ratios
(ICERs) obtained with different algorithms to relate quality
of life (QoL) instruments to preference-based utilities.
METHODS: We determined the ICER of treating primary
insomnia with eszopiclone compared to placebo treatment
based on a model developed using data from a 6-month,
double-blind, placebo controlled, clinical trial to assess the
quality-adjusted life years (QALYs) and costs associated with
eszopiclone treatment. The average 6-month net cost per
patient treated with eszopiclone versus placebo is $69 (2006
USD). QoL data were collected in the trial using the SF-36.
Utilities were derived using 4 algorithms chosen for method-
ological merit (Brazier 2002), applicability to a US population
(Franks 2003 & 2004, Lawrence 2004), and ability to generate
an age- and gender-independent utility (all). All utilize either
the SF-12 or the SF-6D subsets of the SF-36, but differ by:
choice of utility mapped from the QoL instrument (standard
gamble or EQ-5D); items or subscales of the instrument
retained; weighting assigned to the items or subscales; source of
the sample used to value the instrument (UK or US); and theo-
retical range of the predicted utility (e.g., Brazier ranges from
0.35 to 1.0 where Lawrence ranges from 0.15 to 1.01). Other
algorithms were not analyzed because they were not generic
measures, not preference-based, or excluded the vitality domain
(a clinically relevant domain for patients with insomnia).
RESULTS: The four algorithms resulted in average net gains in
6-month QALYs with eszopiclone over placebo of 0.006687,
0.012447, 0.013714, and 0.013800, for the Brazier, Lawrence,
Franks (2004), and Franks (2003) algorithms, respectively.
These data represent mean costs per QALY of $10,261, $5,513,
$5,003, and $4,972, respectively. CONCLUSION: These algo-
rithms, based on either SF-12 item responses or summary
scales, generated cost effective yet different point estimates for
net gain in utilities and the resulting ICERs.
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OBJECTIVES: To develop an analytic method to measure
uncoded disease outcomes in a retrospective claims database.
METHODS: An analysis of multiple sclerosis (MS) patients in a
large, vertically integrated health care system database was con-
ducted with the primary outcome of interest being a relapse
event. MS only has only one International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) code,
which does not specify whether the claim was a result of a relapse
or other event. A review of the literature found no surrogate
markers or composite scores that could be identiﬁable in claims
data. Though Magnetic Resonance Imaging (MRI) is useful in
the treatment of MS, typical claims only report whether or not a
scan was performed and no results or reason for the scan are
available. Utilizing information from published literature and a
physician panel, a treatment pattern was identiﬁed that could be
used in a claims database and would indicate a relapse in MS
patients—two consecutive days of an IV steroid (either methyl-
prednisolone or dexamethasone). The date of relapse was
recorded as the ﬁrst date of IV steroid treatment. RESULTS:
Using a retrospective claims database, a multiple sclerosis (MS)
population utilizing one of four major MS drugs (341 patients)
was identiﬁed. Within the study period (1994–2005), 67 relapses
occurred, deﬁned as two consecutive dates of IV steroid therapy,
which is a common clinical treatment for symptoms related to
MS relapse. This method did not identify all relapses in the study
population; it would be necessary to identify more clinical com-
binations to achieve comparable relapse rates as those found in
the published literature. CONCLUSION: Uncoded events can be
identiﬁed using clinical treatment measures, which are prominent
in claims databases.
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OBJECTIVES: To evaluate the factors of triptan reﬁlling behav-
ior of newly diagnosed female migraineurs. METHODS: This
retrospective analysis utilized data from the i3/Innovus Lab/Rx
database for the period between June 2002 and May 2006.
Included in this study were females between 12 and 49 years of
age with a clinical diagnosis of Migraine (ICD-9-CM 346.xx),
who ﬁlled a prescription for a triptan within two weeks of their
ﬁrst observed migraine diagnosis date (index date). Patients
were required to have 18 months of continuous eligibility.
Logistic regression models were used to evaluate the factors
affecting triptan reﬁlling behavior. RESULTS: A total of 14,343
females were included in the analysis. Within the 12-month
post-index period only 6.5% of the sample ﬁlled two or more
triptan prescriptions. Approximately one-third (38.2%) of these
patients ﬁlled their ﬁrst triptan prescription on their index
migraine diagnosis date, while nearly half (46.8%) ﬁlled their
ﬁrst triptan prescription within 14 days before their index date.
The logistic regression results showed that for each $10 increase
in patient copay, the odds of a subsequent triptan prescription
reﬁll decreased by 8%. Similarly, for each $10 increase in
patient deductible, the odds of reﬁlling decreased by 4%. More-
over, HMO patients were 18% less likely to reﬁll their prescrip-
tions compared to EPO patients. Higher pill counts are
associated with lower probabilities of reﬁlling behavior. Pearson
chi-square tests supported the goodness-of-ﬁt of the test results.
CONCLUSION: These data suggest that most female
migraineurs do not ﬁll more than one triptan prescription
over a one-year time horizon. Out-of-pocket patient expenses
appeared to be the important factors affecting reﬁll behavior.
One implication of these ﬁndings is that many women may be
suffering because of inappropriate management of their
migraine-related pain. Further research into the reasons and
motivations for these outcomes are warranted.
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